Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $127 | $145 | $102 | $142 |
| - Cash | $43 | $45 | $34 | $27 |
| + Debt | $260 | $259 | $258 | $259 |
| Enterprise Value | $344 | $359 | $326 | $374 |
| Revenue | $38 | $29 | $73 | $28 |
| % Growth | 30.3% | -59.8% | 160.8% | – |
| Gross Profit | $34 | $23 | $62 | $23 |
| % Margin | 88.5% | 78.6% | 85.8% | 84.3% |
| EBITDA | -$9 | -$16 | -$2 | -$16 |
| % Margin | -24.1% | -53.3% | -3.4% | -58.2% |
| Net Income | -$15 | -$20 | -$7 | -$25 |
| % Margin | -38.2% | -69% | -9.9% | -90.7% |
| EPS Diluted | -0.25 | -0.35 | -0.13 | -0.46 |
| % Growth | 28.6% | -169.2% | 71.7% | – |
| Operating Cash Flow | -$2 | $11 | -$20 | -$12 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$2 | $11 | -$20 | -$12 |